Compugen to Release Third Quarter 2024 Financial Results on Tuesday, November 12, 2024
Compugen (Nasdaq: CGEN) announced it will release its Q3 2024 financial results on Tuesday, November 12, 2024, before U.S. markets open.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Compugen (Nasdaq: CGEN) announced it will release its Q3 2024 financial results on Tuesday, November 12, 2024, before U.S. markets open. The company will host a conference call and webcast at 8:30 AM ET to discuss financial results and provide a corporate update. Management will also discuss data presented at the Society for Immunotherapy of Cancer Annual Meeting (November 8-10, 2024). The conference call will be accessible via phone and live webcast through Compugen's website, with a replay available afterward.
Details
News Market Reaction – CGEN
The recorded move for CGEN in the trading session of this news was -1.18%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
HOLON,
As part of the update, management will discuss Compugen's data that will have been presented at the Annual Meeting of the Society for Immunotherapy of Cancer, being held on November 8-10, 2024.
To access the live conference call by telephone, please dial 1-866-744-5399 from the U.S.,
or +972-3-918-0644 internationally. The call will be available via live webcast through Compugen's website, located at the following link.
Following the live webcast, a replay will be available on the Company's website.
About Compugen
Compugen is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery platform (Unigen™) to identify new drug targets and biological pathways for developing cancer immunotherapies. Compugen has two proprietary product candidates in Phase 1 development: COM701, a potential first-in-class anti-PVRIG antibody and COM902, a potential best-in-class antibody targeting TIGIT for the treatment of solid tumors. Rilvegostomig, a PD-1/TIGIT bispecific antibody where the TIGIT component is derived from Compugen's clinical stage anti-TIGIT antibody, COM902, is in Phase 3 development by AstraZeneca through a license agreement for the development of bispecific and multispecific antibodies. In addition, the Company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, of which the most advanced program, COM503, a potential first-in-class, high affinity anti-IL-18 binding protein antibody, which has been granted IND clearance from the FDA, is licensed to Gilead. Compugen is headquartered in
Company contact:
Yvonne Naughton, Ph.D.
VP, Head of Investor Relations, and Corporate Communications
Email: ir@cgen.com
Tel: +1 (628) 241-0071
View original content:https://www.prnewswire.com/news-releases/compugen-to-release-third-quarter-2024-financial-results-on-tuesday-november-12-2024-302289893.html
SOURCE Compugen Ltd.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.